157 related articles for article (PubMed ID: 35220649)
1. Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B.
Jung CY; Kim HW; Ahn SH; Kim SU; Kim BS
Liver Int; 2022 May; 42(5):1017-1026. PubMed ID: 35220649
[TBL] [Abstract][Full Text] [Related]
2. Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B.
Jung CY; Kim HW; Lee JI; Lee HW; Ahn SH; Kim SU; Kim BS
Liver Int; 2022 Nov; 42(11):2408-2417. PubMed ID: 35943853
[TBL] [Abstract][Full Text] [Related]
3. Comparison of tenofovir alafenamide and entecavir for hepatitis B virus
Peng W; Gu H; Jiang C; Liu J; Zhang J; Fu L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):194-201. PubMed ID: 35545409
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Ogawa E; Nomura H; Nakamuta M; Furusyo N; Koyanagi T; Dohmen K; Ooho A; Satoh T; Kawano A; Kajiwara E; Takahashi K; Azuma K; Kato M; Shimoda S; Hayashi J;
Liver Int; 2020 Jul; 40(7):1578-1589. PubMed ID: 32304611
[TBL] [Abstract][Full Text] [Related]
5. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.
Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
Hepatol Int; 2021 Oct; 15(5):1083-1092. PubMed ID: 34402025
[TBL] [Abstract][Full Text] [Related]
6. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Liu Z; Zhao Z; Ma X; Liu S; Xin Y
BMC Gastroenterol; 2023 Nov; 23(1):384. PubMed ID: 37950196
[TBL] [Abstract][Full Text] [Related]
7. Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Jeong S; Shin HP; Kim HI
Intervirology; 2022; 65(2):94-103. PubMed ID: 34731856
[TBL] [Abstract][Full Text] [Related]
8. Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.
Kumada T; Toyoda H; Yasuda S; Ito T; Tanaka J
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e898-e904. PubMed ID: 35048656
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients.
Chon HY; Ahn SH; Kim YJ; Yoon JH; Lee JH; Sinn DH; Kim SU
Hepatol Int; 2021 Dec; 15(6):1328-1336. PubMed ID: 34799838
[TBL] [Abstract][Full Text] [Related]
10. Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study.
Sato K; Inoue J; Akahane T; Kobayashi T; Sato S; Kisara N; Ninomiya M; Iwata T; Sano A; Tsuruoka M; Onuki M; Masamune A
Medicine (Baltimore); 2022 Sep; 101(39):e30630. PubMed ID: 36181074
[TBL] [Abstract][Full Text] [Related]
11. Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.
Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
Hepatol Int; 2022 Apr; 16(2):282-293. PubMed ID: 35075593
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir.
Nguyen MH; Atsukawa M; Ishikawa T; Yasuda S; Yokohama K; Trinh HN; Arai T; Fukunishi S; Ogawa E; Hsu YC; Maeda M; Dang H; Tseng CH; Takahashi H; Jun DW; Watanabe T; Chuma M; Nozaki A; Kawada N; Cheung R; Enomoto M; Takaguchi K; Toyoda H
Am J Gastroenterol; 2021 Jun; 116(6):1264-1273. PubMed ID: 34074829
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy.
Lee IC; Lan KH; Su CW; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232631
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir.
Yuan GC; Chen AZ; Wang WX; Yi XL; Tu L; Peng F; Qiu ZH
World J Clin Cases; 2023 Dec; 11(34):8139-8146. PubMed ID: 38130795
[TBL] [Abstract][Full Text] [Related]
15. Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B: Systematic review with meta-analysis.
Lee HY; Oh H; Park CH; Yeo YH; Nguyen MH; Jun DW
World J Gastroenterol; 2019 Jun; 25(23):2961-2972. PubMed ID: 31249453
[TBL] [Abstract][Full Text] [Related]
16. Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients.
Tsai HJ; Chuang YW; Lee SW; Wu CY; Yeh HZ; Lee TY
Aliment Pharmacol Ther; 2018 Jun; 47(12):1673-1681. PubMed ID: 29696665
[TBL] [Abstract][Full Text] [Related]
17. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
Aliment Pharmacol Ther; 2022 Aug; 56(4):713-722. PubMed ID: 35735794
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study.
Peng W; Gu H; Cheng D; Chen K; Wu C; Jiang C; Liu J; Peng S; Fu L
Front Microbiol; 2023; 14():1185492. PubMed ID: 37303805
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study.
Mak LY; Hoang J; Jun DW; Chen CH; Peng CY; Yeh ML; Kim SE; Huang DQ; Jeong JY; Yoon E; Oh H; Tsai PC; Huang CF; Ahn SB; Trinh H; Xie Q; Wong GLH; Enomoto M; Shim JJ; Lee DH; Liu L; Kozuka R; Cho YK; Jeong SW; Kim HS; Trinh L; Dao A; Huang R; Hui RW; Tsui V; Quek S; Khine HHTW; Ogawa E; Dai CY; Huang JF; Cheung R; Wu C; Chuang WL; Lim SG; Yu ML; Yuen MF; Nguyen MH
Hepatol Int; 2022 Feb; 16(1):48-58. PubMed ID: 34822056
[TBL] [Abstract][Full Text] [Related]
20. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia.
Charlton MR; Alam A; Shukla A; Dashtseren B; Lesmana CRA; Duger D; Payawal DA; Duy Cuong D; Jargalsaikhan G; Cua IHY; Sollano JD; Singh KR; Madan K; Win KM; Kyi KP; Tun KS; Salih M; Rastogi M; Saraf N; Thuy PTT; Hien PTD; Gani RA; Mohamed R; Tanwandee T; Piratvisuth T; Sukeepaisarnjaroen W; Naing W; Hashmi ZY
J Gastroenterol; 2020 Sep; 55(9):811-823. PubMed ID: 32666200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
